ChemDiv and Insilico Medicine Form A Strategic Alliance to Develop Oncology Focused Libraries Using Artificial Intelligence 

ChemDiv and Insilico Medicine Form A Strategic Alliance to Develop Oncology Focused Libraries Using Artificial Intelligence 

ChemDiv, Inc. and Insilico Medicine, Inc. announced the signing of a collaboration agreement aimed at partnering to develop and market annotated compound libraries targeting various types of cancer. These innovative libraries will advance the discovery of new oncology drug candidates. 
Insilico Medicine’s pharmaceutical artificial intelligence platform based on expertise in ‘omics’ data analysis and deep learning methods will add a valuable annotated component to ChemDiv’s anticancer library, and, combined with ChemDiv’s proprietary chemistry focused on small molecule drug development, will provide several thousand new oncology candidates. 
The first product line will contain the libraries of novel compounds against 18 types of cancer, including bladder urothelial carcinoma, breast invasive carcinoma, endocervical adenocarcinoma, colon and rectal cancer, kidney renal papillary cell carcinoma, lung adenocarcinoma, prostate adenocarcinoma, sarcoma. 
“We are very excited about our collaboration with Insilico Medicine and our new project aimed at rapidly targeting various types of cancer,” said Sergey Bugrov, Executive Director, ChemDiv. “This target-focused alliance with Insilico Medicine adds to our existing programs focused on developing high value drug candidates for future oncology therapeutics.” 
Alex Zhavoronkov, CEO of Insilico Medicine, added, “This strategic alliance with ChemDiv is a unique opportunity for us to expand our portfolio of focused products and services. Our proprietary technologies and expertise in drug discovery and repurposing using deep learning methods are complementary to ChemDiv’s proprietary technologies in the area of focused library development and, thus, our partnership may result in many valuable discoveries.” 
About ChemDiv, Inc.
ChemDiv is a recognized global leader in discovery chemistry with one of the industry’s largest, most diverse, and most productive collections of over 1,600,000 individually crafted, lead-like, drug-like small molecules. Over the past 25 years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv’s integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond. ChemDiv’s laboratories are equipped for both ‘GLP-like’ and GLP research standards to meet international research and business partners’ needs. http://www.chemdiv.com/ 
About Insilico Medicine, Inc.
Insilico Medicine is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson’s, Alzheimer’s, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. http://insilicomedicine.com/

Media Contact
Ronald Demuth 
Senior VP, ChemDiv 
Email: [email protected] 
Phone: +1-858-794-4860

September 8, 2016 / News